A review published in
Genes & Diseases highlights how RNA molecules could open new avenues for diagnosing and treating
heart disease. Researchers from Shandong Second Medical University and Qingdao University examine four groups of non-coding RNAs that influence abnormal heart muscle growth, damage caused by reduced blood supply, and heart failure.
Unlike RNAs that provide instructions for making proteins,
non-coding RNAs help regulate cellular activity. The review focuses on
small nucleolar RNAs,
PIWI-interacting RNAs,
tRNA-derived small RNAs, and
circular RNAs. These molecules are attracting attention as potential biomarkers and therapeutic targets beyond the better-studied microRNAs and long non-coding RNAs.
The article brings together evidence that these RNA groups can affect gene activity, protein function, cell survival, and
cardiac fibrosis, the formation of scar tissue in the heart. Their effects vary: some molecules promote damage, while others appear to protect heart cells or limit harmful structural changes.
Circular RNAs receive attention because their downstream mechanisms are comparatively well characterised. They can interact with proteins or influence networks involving microRNAs and messenger RNAs, altering pathways linked to cardiac growth, inflammation, and cell death. Research into the other three RNA groups is developing, although many functional mechanisms remain uncertain.
The review describes experimental findings that illustrate
therapeutic possibilities. In mice, inhibiting a PIWI-interacting RNA called
CHAPIR reduced pathological heart muscle enlargement, lessened fibrosis, and improved cardiac performance. Targeting another molecule,
CFRPi, also reduced fibrosis and improved heart function in a mouse model of pressure overload.
Potential diagnostic applications are emerging alongside these treatment strategies. Studies have identified altered RNA levels in blood samples from people with heart attacks, hypertrophic cardiomyopathy, and heart failure. Such patterns could help identify disease or assess progression. Some findings suggest combining RNA measurements with established cardiac markers could improve
diagnostic performance.
However, these opportunities remain under investigation. Animal results do not establish that RNA-targeted treatments will work safely in patients, and candidate biomarkers require further
clinical validation. Researchers must also determine whether altered RNA levels cause disease, contribute to its progression, or simply reflect existing damage.
Developing therapies will require delivery to the heart, control of unintended effects, and assessment of toxicity and
long-term safety. Understanding interactions between RNA groups will also be important.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Diseases may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)
# # # # # #
Reference
Jingyi Wang, Jingyi Xie, Hao Chen, Wenxu Wang, Qing Liu, Xuanzhen Guo, Kun Wang, Jie Ju, The emerging roles of small nucleolar RNAs, piwi-interacting RNAs, tRNA-derived small RNAs, and circular RNAs in the regulation of cardiac hypertrophy, ischemic heart disease, and heart failure, Genes & Diseases, Volume 13, Issue 6, 2026, 101996,
https://doi.org/10.1016/j.gendis.2025.101996
Funding
National Natural Science Foundation (China) 82500356
Shandong Provincial Natural Science Foundation ZR2025QC863
PhD research startup foundation of Shandong Second Medical University (China)
0215500104
Weifang science and technology development plan project for medicine (China)
2025YX039
Weifang science and technology development plan project for medicine (China)
2024YX036
Shandong Second Medical University innovation and entrepreneurship training program (China)
X2024281